Skip to content

    Cytek Biosciences (CTKB) stock price & financials

    View CTKB earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+14.4% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $51.50M
    $57.48M
    $41.46M
    $45.60M
    $52.29M
    +1.5%
    $62.14M
    +8.1%
    $44.13M
    +6.5%
    $48.14M
    +5.6%
    Strengthening
    Operating Profit
    -$4.25M
    $2.99M
    -$14.97M
    -$10.62M
    -$9.19M
    -116.4%
    -$5.59M
    -287.3%
    -$18.46M
    -23.3%
    -$11.40M
    -7.3%
    Weakening
    Net Profit
    -$11.40M
    -$5.58M
    -$18.87M
    -65.5%
    -$12.16M
    -117.8%
    Weakening
    EPS
    Other Income
    $4.41M
    $7.34M
    $3.71M
    $3.85M
    $1.42M
    -67.7%
    $1.56M
    -78.7%
    $1.09M
    -70.6%
    -$243.0K
    -106.3%
    Weakening
    Interest
    $119.0K
    -$5.93M
    $291.0K
    $414.0K
    $494.0K
    +315.1%
    -$725.0K
    +87.8%
    $262.0K
    -10.0%
    $281.0K
    -32.1%
    Strengthening
    Depreciation
    Profit before Tax
    $157.0K
    $10.32M
    -$11.27M
    -$6.78M
    -$7.77M
    -5048.4%
    -$4.03M
    -139.1%
    Weakening
    MarginsOPM
    -8.3%
    5.2%
    -36.1%
    -23.3%
    -17.6%
    -113.1%
    -9.0%
    -273.1%
    -41.8%
    -15.8%
    -23.7%
    -1.6%
    Weakening
    Tax
    -499.4%
    6.6%
    -1.2%
    17.6%
    29.5%
    -993.4%
    -15174.8%
    Weakening
    ReturnsROIC
    8.6%
    4.2%
    14.2%
    +65.5%
    9.2%
    +117.8%
    Strengthening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$165.23M$364.62M$296.60M$167.30M$98.72M$90.85M$73.85M
    Short-Term Investments
    Total Current Assets$208.62M$431.73M$454.02M$392.06M$396.45M$392.00M$377.93M
    Net PP&E$2.14M$5.85M$27.57M$29.26M$28.13M$29.32M$31.76M
    Goodwill$476.0K$10.14M$10.14M$16.18M$16.66M$16.70M$16.69M
    Intangibles$274.0K$4.74M$4.33M$23.08M$20.13M$16.82M$14.87M
    Total Assets$219.98M$463.31M$519.48M$494.46M$499.50M$461.54M$446.93M
    LiabilitiesTotal Current Liabilities$26.54M$33.18M$49.04M$56.23M$67.66M$77.80M$84.33M
    Short-Term Debt
    Long-Term Debt
    Long-Term Leases$0$12.31M$9.48M$7.55M$14.04M$13.52M
    Total Liabilities$41.69M$57.92M$93.93M$101.39M$103.76M$119.80M$124.98M
    EquityCommon Stock & APIC$23.0K$126.0K$135.0K$131.0K$129.0K$129.0K$130.0K
    Retained Earnings-$22.61M-$19.61M-$17.03M-$29.18M-$35.20M-$101.74M-$132.76M
    Total Equity-$16.03M$405.38M$425.55M$393.06M$395.74M$341.74M$321.95M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating$15.16M$4.63M-$12.23M$5.28M$25.38M-$4.69M-$6.04M
    Cash from Investing-$1.55M-$20.99M-$55.91M-$93.89M-$82.97M$10.12M-$2.98M
    Cash from Financing$122.61M$213.56M$5.51M-$41.81M-$15.82M-$13.43M$3.88M
    SummaryCapital Expenditure-$1.55M-$4.36M-$9.75M-$4.65M-$3.52M-$4.08M-$6.04M
    Free Cash Flow$13.61M$266.0K-$21.98M$633.0K$21.85M-$8.77M-$12.08M
    FCF Margin1916.8%12.2%-741.8%0.3%10.9%-4.4%-5.8%

    Ratios